Assessing determinants of breast cancer patients in Indonesia for delayed diagnosis, treatment, risks of relapse, and survival

ISRCTN ISRCTN13788093
DOI https://doi.org/10.1186/ISRCTN13788093
Secondary identifying numbers INABrC01
Submission date
29/09/2020
Registration date
02/10/2020
Last edited
08/06/2022
Recruitment status
Recruiting
Overall study status
Ongoing
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English Summary

Background and study aims
Breast cancer is the most common cancer among women worldwide including in Indonesia. The death rates of breast cancer patients are significantly higher in developing countries including in Indonesia in comparison those in developed nations. The aim of this study is to collect a variety of data from patients diagnosed with breast cancer in order to define specific characteristics and recurrence rates, progression, and overall survival in breast cancer patients.

Who can participate?
Patients aged over 18 years old with a diagnosis of breast cancer from 2014 to 2022

What does the study involve?
The study involves collecting information on the risk factors, course of the disease, the response to different treatments, recurrence rates, progression, and death from cancer. There is an optional choice to provide a number of blood or tissue samples for the duration of diagnosis, treatment, and follow-up.

What are the possible benefits and risks of participating?
There are no specific risks or benefits to participants.

Where is the study run from?
Universitas Gadjah Mada / Dr Sardjito Hospital, Yogyakarta (Indonesia)

When is the study starting and how long is it expected to run for?
January 2018 to December 2026

Who is funding the study?
Universitas Gadjah Mada (Indonesia)

Who is the main contact?
1. Dr Sumadi Lukman Anwar
sl.anwar@ugm.ac.id
2. Prof. Dr. Teguh Aryandono
teguharyandono@yahoo.com

Contact information

Dr Sumadi Lukman Anwar
Public

Department of Surgery
Dr Sardjito Hospital/Faculty of Medicine
Universitas Gadjah Mada
Jl. Kesehatan 01
Yogyakarta
55281
Indonesia

ORCiD logoORCID ID 0000-0002-2607-6682
Phone +62-274-581333
Email sl.anwar@ugm.ac.id

Study information

Study designObservational cohort
Primary study designObservational
Secondary study designCohort study
Study setting(s)Hospital
Study typeScreening
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleAssessing demographic, social, clinical, and pathological determinants of breast cancer patients for delayed diagnosis, treatment, risks of relapse, and survival
Study acronymINABrC
Study hypothesisDemographic, social, clinical, and pathological determinants are associated with delayed diagnosis, risks of relapse, and survival of breast cancer diagnosed and treated according to the local and national guidelines in Indonesia
Ethics approval(s)Approved 20/10/2017, Ethics Committee of the Faculty of Medicine, Public Health, and Nursing (Universitas Gadjah Mada Yogyakarta, Jl Farmako Sekip Utara - Gedung Radiopetro 2nd Floor, Yogyakarta 55281, India; +62-274-588688-17225; mhrec_fmugm@ugm.ac.id), ref: 1143/EC/2017
ConditionSociodemographic and clinicopathological determinants in breast cancer diagnosis and prognosis
InterventionIn this study, sociodemographic and clinicopathological variables will be collected and breast cancer patients will be followed-up for the locoregional recurrence, progression into distant metastasis, and survival.

The patient will be interviewed using a questionnaire (15-20 minutes to complete) to assess risks of breast cancer and general awareness of cancer and cancer screening. The patient will then be followed-up for minimum of 6 months. Medical records will be extracted to collect information of clinical and pathological variable including the follow-up examination according to the local clinical guidances (every 6 months examination of sonography, x-ray, and yearly mammography). A blood sample is optional if the patient agrees to donate for additional examination, 5-10 ml of whole blood will be taken and stored at the biobank.
Intervention typeOther
Primary outcome measureOverall survival at the end of the study measured using patient records
Secondary outcome measures1. Sociodemographic backgrounds, occupation, income, general understanding of cancer, and hormonal factors such as menarche, menopause, BMI, contraception, number of children, breastfeeding practice, and usage of hormonal replacement therapy measured using a novel questionnaire at baseline
2. Cancer progression into distant metastasis, defined as presence of cancer spread to the lung, bone, liver, and brain indicating with clinical manifestations and were confirmed with imaging/pathology examination and/or radiologic changes confirmed with computed tomography imaging with contrast or whole-body bone scan every 6 months after baseline
3. Other clinical findings revealed by thorough clinical examination and imaging conducted at routine follow up visits retrieved from patient records
Overall study start date06/01/2018
Overall study end date31/12/2026

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexFemale
Target number of participants2,000
Participant inclusion criteria1. Confirmed breast cancer according to the pathology report
2. Participants are able to provide written informed consent (over 18 years old)
3. No emergency procedure is required during the first presentation
Participant exclusion criteria1. Vulnerable breast cancer patients
Recruitment start date06/04/2018
Recruitment end date30/06/2026

Locations

Countries of recruitment

  • Indonesia

Study participating centre

Universitas Gadjah Mada
Dr Sardjito Hospital
Jl Kesehatan No 1
Yogyakarta
55281
Indonesia

Sponsor information

Universitas Gadjah Mada
University/education

Faculty of Medicine
Jl Farmako
Sekip Utara
Yogyakarta
55281
Indonesia

Phone +62-274-560300
Email fku@ugm.ac.id
Website https://fk.ugm.ac.id/en/

Funders

Funder type

University/education

Universitas Gadjah Mada

No information available

NUS-UGM-Tahir Foundation

No information available

Results and Publications

Intention to publish date01/12/2026
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planPlanned publication in a high-impact peer-reviewed international journal. Raw data without any identification of participants will be shared according to the WHO and ICMJE.
IPD sharing planThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request

Editorial Notes

08/06/2022: The following changes have been made:
1. The recruitment end date has been changed from 30/06/2022 to 30/06/2026.
2. The overall trial end date has been changed from 31/12/2022 to 31/12/2026 and the plain English summary has been updated to reflect this change.
3. The intention to publish date has been changed from 01/12/2023 to 01/12/2026.
02/10/2020: Trial’s existence confirmed by Universitas Gadjah Mada Yogyakarta